Evogene Ltd. logo

Evogene Ltd.

EVGN

NASDAQHealthcareBiotechnology

前收盤價

US$0.5625

+US$0.002 · +0.36%

8月21日 下午4:00 ET

盤前

US$0.5806

+US$0.0181 · +3.22%

8月24日 上午4:26 ET

EVGN公司概覽

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

29

Expensive

動能

20

Strong Down

情緒

60

Mixed

風險韌性

31

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考,並非投資建議。

公司概況

公司網站

Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.

產業
Biotechnology
部門
Healthcare
總部
IL
執行長
Ofer Haviv
上市以來
2010年10月15日
僱員
52

市場位置

日內區間

目前US$0.5625,

52週區間

目前US$0.5625,

開盤價
US$0.5437
前收盤價
US$0.5605
成交量
104.2萬
0.78× 平均值
平均成交量
133.26萬
日均成交量
市值
484.7萬 USD
貝塔
0.78
市場參考 1
50天平均值
US$0.5336
高於平均水平+5.42%
200天平均值
US$0.8247
低於平均水平-31.79%

分析師評級

第三方分析師預期可能變動,並非 GoAI 建議。

近期分析師行動

1 機構

EVGN同業公司

繼續GoAI的研究

在 GoAI 中研究EVGN

research.disclaimer